Cybin Inc.

Equities

CYBN

CA23256X1006

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:00 07/06/2024 BST			5-day change	1st Jan Change
0.2898 ^USD	+0.07%		-17.20%	-29.32%

05-06	Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	CI
04-17	Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	MT

Cybin Inc. Announces Election of Theresa Firestone as Director

August 16, 2021 at 11:29 pm

Cybin Inc. announced that Theresa Firestone has been elected to its board of directors at the Company’s annual and special meeting of shareholders held on August 16, 2021 (the “Meeting”). Ms. Firestone is a senior healthcare executive with retail, pharmaceutical, health and wellness, government and global restructuring expertise and the Company is excited to welcome Ms. Firestone to its board of directors.

Latest news about Cybin Inc.

Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	05-06	CI
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	04-17	MT
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	04-16	MT
Cybin Inc. announced that it has received $150 million in funding from a group of investors	03-18	CI
Sector Update: Health Care Stocks Softer Friday Afternoon	03-15	MT
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	03-15	MT
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	03-15	CI
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial	03-14	MT
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	03-14	CI
Sector Update: Health Care Stocks Ease Wednesday Afternoon	03-13	MT
Cybin Says Depression Drug Granted Breakthrough Designation by FDA; Raises $150 Million in Private Placement; Shares Jump	03-13	MT
Transcript : Cybin Inc. - Special Call	03-13
Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder	03-13	CI
Cybin Inc. announced that it expects to receive $150 million in funding	03-12	CI
Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Cybin Gets FDA Clearance for Generalized Anxiety Disorder Study	01-23	MT
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder	01-23	CI
Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028	01-08	CI
Cybin Inc. Announces Recent Positive Phase 2 CYB003 Topline Results in MDD and Outlines Key Upcoming Milestones Across its Clinical Development Programs	01-04	CI
Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting	12-06	CI
Transcript : Cybin Inc. - Special Call	11-30
Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses	11-30	CI
HC Wainwright Adjusts Cybin Price Target to $5 From $10, Maintains Buy Rating	11-17	MT
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-13	CI
Transcript : Cybin Inc. - Special Call	11-01

Chart Cybin Inc.

Duration

Period

More charts

Company Profile

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Sector

Biotechnology & Medical Research

Calendar

01:20pm - Interdisciplinary Psychedelic Research Conference - Panel

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3986 CAD

Average target price

6.089 CAD

Spread / Average Target

+1,427.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYBIN INC.	-29.32%	220M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B

Bio Therapeutic Drugs